Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Shorted Shares Increased 52.88% After Market Selling

April 17, 2018 - By Ellis Scott

The stock of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) registered an increase of 52.88% in short interest. AGLE’s total short interest was 31,800 shares in April as published by FINRA. Its up 52.88% from 20,800 shares, reported previously. With 102,900 shares average volume, it will take short sellers 0 days to cover their AGLE’s short positions. The short interest to Aeglea Biotherapeutics Inc’s float is 0.48%.

The stock increased 5.88% or $0.53 during the last trading session, reaching $9.54. About 24,791 shares traded. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) has risen 26.34% since April 17, 2017 and is uptrending. It has outperformed by 14.79% the S&P500.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company has market cap of $159.47 million. The Company’s human enzymes are designed to degrade specific amino acids in the blood. It currently has negative earnings. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.